期刊文献+

氟尿嘧啶免疫聚乳酸纳米微粒抗肿瘤效应的研究 被引量:5

Study of the anti-tumor effect of anti-vascular endothelial growth factor McAb 5-fluorouracil loaded polylactic acid nanoparticles
原文传递
导出
摘要 目的利用载氟尿嘧啶(5-FU)免疫聚乳酸(PEA)纳米微粒(NPs),观察其对严重联合免疫缺陷病(SCID)鼠人胃癌移植模型的治疗效应。方法超声乳化法合成的载5-FU的抗血管内皮生长因子(VEGF)单克隆抗体纳米微粒,建立SCID鼠人胃癌移植肿瘤模型,观察药物对高表达VEGF胃癌移植肿瘤模型的治疗效应及其不良反应。结果空白对照组、未载药空纳米微粒组、5-FU组(20mg/kg)、抗VEGF单克隆抗体-未载药空纳米微粒组、抗VEGF单克隆抗体组、载5-FU纳米微粒组、5-FU(20mg/kg)加抗VEGF单克隆抗体组及抗VEGF单克隆抗体-载5-FU纳米微粒组(20mg/kg)的抑瘤率分别为0、6.61%、24.26%、27.94%、35.29%、37.50%、39.71%和52.21%,且载5-FU的抗VEGF单克隆抗体纳米微粒组和未载药纳米微粒组的血白细胞数量及肝肾功能与空白对照组相比,差异无统计学意义(P〈0.05);而含5-FU原药组血白细胞数量较空白对照组和抗VEGF单克隆抗体-载5-FU纳米微粒组下降34.43%和37.38%(P〈0.05):而肝转氨酶升高93.17%和66.56%。治疗组与对照组癌细胞凋亡指数相比,以抗VEGF单克隆抗体.载5-FU纳米微粒组更为明显,差异有统计学意义(P〈0.05);含抗VEGF抗体的实验组微血管密度明显低于含5-FU药组和对照组(P〈0.05)。结论载5-FU抗VEGF单克隆抗体纳米微粒可提高5-FU的抑瘤率,并通过抑制肿瘤的血管生成,诱导肿瘤细胞凋亡,增加疗效,有效降低5-FU的骨髓抑制和肝肾功能损害作用.是一种安全的新型药物纳米级靶向制剂。 Objective To explore the anti-tumor efficacy of anti- vascular endothelial growth factor (VEGF)McAb 5-fluorouracil (5-FU)loaded polylactic acid (PEA) nanoparticles (NPS) in human gastric carcinoma xenografts of nude mice. Methods Anti-VEGF McAb 5-FU loaded PLA NPS were made by ultrasound emulsification. Nude mice model of human gastric carcinoma xenografts was established. Therapeutic effects of drugs on human gastric carcinoma xenografts and side effects concerned were observed. Results The tumor inhibition rates of control group, nanosphere without 5- FU group, 5-FU (20 mg/kg) group, anti-VEGF McAb nanosphere without 5-FU group, anti-VEGF McAb group, nanosphere with 5-FU group, 5-FU (20 mg/kg) combined with anti-VEGF McAb group, anti-VEGF McAb 5-FU loaded nanosphere group was O, 6.61%, 24.26%, 27.94%, 35.29%, 37.50%, 39.71% and 52.21% respectively, and there were no significant differences between anti-VEGF McAb 5-FU loaded nanosphere group and nanosphere group without 5-FU in WBC count, serum alanine transferase level or creatinine level. Compared with control group and anti-VEGF McAb 5-FU loaded nanosphere group, the 5-FU group decreased by 34.43% and 37.38% respectively in WBC count (P〈0.05), and increased by 93.17% and 66.56% respectively in alanine transferase. There were significant differences between experimental groups and control group in apoptosis index, especially between anti-VEGF McAb 5-FU loaded nanosphere group and control group(P〈0.05). The microvessel density (MVD) of experimental groups containing anti-VEGF McAb was significantly lower than that of control group or groups containing 5-FU (P〈0.05). Conclusion Anti-VEGF McAb 5-FU loaded nanosphere can increase the tumor inhibitory rate of 5-FU, induce apoptosis by inhibiting tumor angiogenesis with less side effect, and then enhance therapeutic effect, which indicate its potential as a novel, safe nano-tumor-targeting drug.
出处 《中华胃肠外科杂志》 CAS 2007年第5期482-485,共4页 Chinese Journal of Gastrointestinal Surgery
基金 国家自然科学基金(30670951) 广东省自然科学基金(06021322) 广州市科技攻关项目(2003Z3-E0381):广东省科技攻关项目(2005B31211002)
关键词 氟尿嘧啶 聚乳酸 载药纳米微粒 胃肿瘤 血管生成 凋亡 5-fluorouracil Polylactic acid Drug loaded nanoparticles Stomach neoplasms Angiogenesis Apoptosis
  • 相关文献

参考文献7

  • 1Ohtsu A. Current status and future prospects of chemotherapy for metastatic gastric cancer: a review. Gastric Cancer, 2005, 8:95-102. 被引量:1
  • 2Wohrer SS, Raderer M, Hejna M. Palliative chemotherapy for advanced gastric cancer. Ann Oncol, 2004,15 : 1585-1595. 被引量:1
  • 3Yoshida M, Ohtsu A, Boku N, et al. Long-term survival and prognostic factors in patients with metastatic gastric cancers treated with chemotherapy in the Japan Clinical Oncology Grouo (JCOG) study. Jon J Clin Oncol, 2004.34:654-659. 被引量:1
  • 4黄开红,朱兆华,刘建化,陈其奎,刘晓燕,常津.聚乳酸载药纳米微粒制备及其释药效能[J].癌症,2005,24(8):1023-1026. 被引量:25
  • 5Bilati U, Allemann E, Doelker E. Nanoprecipitation versus emulsion-based techniques for the encapsulation of proteins into biodegradable nanoparticles and process-related stability issues. AAPS Pharm Sci Tech, 2005,6:E594-604. 被引量:1
  • 6Visaria RK, Griffin R J, Williams BW, et al. Enhancement of tumor thermal therapy using gold nanoparticle-assisted tumor necrosis factor-alpha delivery. Mol Cancer Ther, 2006,5:1014- 1020. 被引量:1
  • 7阚和平,田伏洲,刘晓波,李小军.抗人大肠癌免疫毫微球的制备及其抗癌效果观察[J].中国普外基础与临床杂志,2001,8(1):1-4. 被引量:2

二级参考文献17

  • 1刘民培,马英世,陈伟,戴兵,邹燕玲,王笑利,安天义,宋于刚,初俊杰.抗大肠癌相关抗原SC系列单抗的研究及其应用[J].中国肿瘤,1993,2(11):27-27. 被引量:3
  • 2隋延仿,刘利,陈志南,刘彦仿,王文亮.双弹头组合单抗免疫导向治疗肝癌的实验研究[J].癌症,1996,15(3):168-171. 被引量:4
  • 3张志荣.肝靶向米托蒽醌白蛋白微球的研究[J].药学学报,1997,32(1):72-78. 被引量:22
  • 4Smith JP, Stock E, Orenberg EK, et al. Intratumoral chemotherapy with a sustained-release drug delivery system inhibits growth of human pancreatic cancer xenografts [J]. Anticancer Drugs, 1995,6(6) :717-726. 被引量:1
  • 5Hussain M, Beale G, Hughes M, et al. Co-delivery of an antisense oligonucleotide and 5-fluorouracil using sustained release poly (lactide-coglycolide) microsphere formulations for potential combination therapy in cancer [J]. IntJ Pharm, 2002,234 (1-2):129-138. 被引量:1
  • 6Nagaich S, Khopade AJ, Jain NK.Lipid grafts of egg-box complex: a new supramolecular biovector for 5 -fluorouracil delivery [J]. Pharm Acta Helv, 1999,73: 227-236. 被引量:1
  • 7Kwon GS, Okano T. Polymeric micelles as new drug carriers [J]. Adv Drug Deliv Rev, 1996, 21:107-116. 被引量:1
  • 8Tobio M, Gref R, Sanchez A, et al.Stealth PLA-PEG nanoparticles as protein carriers for nasal administration [J]. Pharm Res, 1998,15 (2):270-275. 被引量:1
  • 9Zhang Y, Zhang QH, Zha LS, et al.Preparation, characterization and application of pyrene-loaded methoxy poly(ethylene glycol)-poly(lactic acid)opolymer nanoparticles [J]. Colloid Polym Sci, 2004,282 (12): 1323-1328. 被引量:1
  • 10Dunn SE, Coombes AGA, Garnett MC,et al. In vitro cell interaction and in vivo biodistribution of poly (lactide-coglycolide) nanospheres surface modified by poloxamer and poloxamine copolymers [J]. J Controlled Release, 1997,44(1):65-71. 被引量:1

共引文献25

同被引文献44

引证文献5

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部